Giorli A, Ferretti F, Biagini C, Salerni L, Bindi I, Dasgupta S, Pozza A, Gualtieri G, Gusinu R, Coluccia A, Mandalà Marco
Otolaryngology Department, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Dipartimento Scienze Mediche Chirurgiche e Neuroscienze, Università di Siena, Siena, Italy.
Curr Treat Options Neurol. 2020;22(10):36. doi: 10.1007/s11940-020-00641-5. Epub 2020 Aug 28.
To investigate the association between the olfactory dysfunction and the more typical symptoms (fever, cough, dyspnoea) within the Sars-CoV-2 infection (COVID-19) in hospitalized and non-hospitalized patients.
PubMed, Scopus and Web of Science databases were reviewed from May 5, 2020, to June 1, 2020. Inclusion criteria included English, French, German, Spanish or Italian language studies containing original data related to COVID19, anosmia, fever, cough, and dyspnoea, in both hospital and non-hospital settings. Two investigators independently reviewed all manuscripts and performed quality assessment and quantitative meta-analysis using validated tools. A third author arbitrated full-text disagreements. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), 11 of 135 studies fulfilled eligibility. Anosmia was estimated less prevalent than fever and cough (respectively rate difference = - 0.316, 95% CI: - 0.574 to - 0.058, = - 2.404, < 0.016, = 11 and rate difference = - 0.249, 95% CI: - 0.402 to - 0.096, = - 3.185, < 0.001, = 11); the analysis between anosmia and dyspnoea was not significant (rate difference = - 0.008, 95% CI: - 0.166 to 0.150, Z = - 0.099, < 0.921, = 8). The typical symptoms were significantly more frequent than anosmia in hospitalized more critical patients than in non-hospitalized ones (respectively [(1) = 50.638 < 0.000, (1) = 52.520 < 0.000, (1) = 100.734 < 0.000).
Patient with new onset olfactory dysfunction should be investigated for COVID-19. Anosmia is more frequent in non-hospitalized COVID-19 patients than in hospitalized ones.
研究住院和非住院患者中,嗅觉功能障碍与新型冠状病毒感染(COVID-19)中更典型症状(发热、咳嗽、呼吸困难)之间的关联。
对2020年5月5日至2020年6月1日期间的PubMed、Scopus和Web of Science数据库进行了检索。纳入标准包括英文、法文、德文、西班牙文或意大利文的研究,这些研究包含在医院和非医院环境中与COVID-19、嗅觉丧失、发热、咳嗽和呼吸困难相关的原始数据。两名研究人员独立审查了所有手稿,并使用经过验证的工具进行质量评估和定量荟萃分析。第三位作者对全文分歧进行仲裁。按照系统评价和荟萃分析的首选报告项目(PRISMA),135项研究中有11项符合资格标准。嗅觉丧失的发生率估计低于发热和咳嗽(率差分别为=-0.316,95%CI:-0.574至-0.058,=-2.404,<0.016,=11;率差=-0.249,95%CI:-0.402至-0.096,=-3.185,<0.001,=11);嗅觉丧失与呼吸困难之间的分析无统计学意义(率差=-0.008,95%CI:-0.166至0.150,Z=-0.099,<0.921,=8)。在住院的重症患者中,典型症状比嗅觉丧失更常见,且比非住院患者更频繁(分别为[(1)=50.638<0.000,(1)=52.520<0.000,(1)=100.734<0.000])。
新发嗅觉功能障碍的患者应接受COVID-19调查。非住院COVID-19患者的嗅觉丧失比住院患者更常见。